Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #4   Immuno-Oncology in Adjuvant/Neoadjuvant Settings .     According to a Crédit Suisse analysis, the adjuvant immuno-oncology (I-O) market could reach $29 billion in peak sales.   The study considers the various I-O therapies intended to reduce the risk […]

         Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com   SPECIAL REPORT #3   2018: A Record Year for Global Cancer Treatment Approvals     The publication of an annual review of global oncology approvals, by Bruno Pagliara, Principal at On-Kòs Pharma, has become a highly appreciated and comprehensive analysis of the activity […]

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #2     Cell and Gene Therapy: The next wave of innovation?     With three gene therapy products already on the market and the approval of the first chimeric antigen receptor (CAR) T cell treatments, Kymriah (tisagenlecleucel) and Yescarta (axibactagene, […]

    Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #1     The US FDA has approved 59 NMEs (new medical entities) in 2018 topping its previous record of 53 in 1996.     This impressive showing follows a 46 NMEs approvals in 2017 and a low 22 new […]

    Btobioinnovation.com     Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     Dear Readers,   We wish all of you a Happy and Joyful Year 2019. A short reading indication that it is never to late in life to improve cognitive performance. Best regards Jean-Claude Muller   Diet and Exercise Might Reverse Aging […]